Clinical experience with respect to safety & efficacy of polyclonel anti D immunoglobulin for intravenous use (KamRho D IV) for management of thrombocytopenia of varied origin.

<p><strong>Background: </strong>Severe thrombocytopenia is one of the major manifestations of many critical emergencies apart from idiopathic thrombocytopenic purpura (ITP), Lymphoproliferative disorders and Myelodysplastic syndrome (MDS). <strong>Objective:</strong> Present study was carried out to study efficacy and safety of polyclonal Anti-D i.v immunoglobulin in thrombocytopenia of varied origin other than ITP, MDS and Lymphoproliferative disorders. Method: This was a prospective clinical trial 3 carried out on 28 adults with thrombocytopenia of varied origin with platelet count less than 35000 / mm . They were given polyclonal Anti D immunoglobulin by iv route. The dose was 75 &micro;g/kg body weight, as a bolus, after enrolling the patients. The rise in platelets was observed daily for three consecutive days and then at day 7. Hb % levels were observed on day 1, 2 and 7. <strong>Results :</strong> efficacy -Out of 26 patients included 57% responded to kamRho D IV within 24 hrs, with a significant rise in platelet counts. After 48 hrs the percentage of respondents increased to 88.5% and after 72 hrs there were no non-respondents left in the study population. 96% of patients has platelet count above 100,000 after day 7. Safety : Of 26 patients 23 showed a fall in haemoglobin % level. The mean decrease in Hb % was 1.39 gm/dl. There were no side effects. <strong>Conclusion:</strong> Intravenous Anti-D is safe, effective and well tolerated treatment in secondary thrombocytopenia of varied origin. IV Anti-D can be safe alternative for secondary thrombocytopenia where immediate platelet transfusion is not available.&nbsp;</p>